Safety evaluation and therapeutic effect of Levosimendan on the low cardiac output syndrome in patients after cardiopulmonary bypass

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016594

Enrollment

Unknown

Registered

2018-06-11

Start date

2018-06-16

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease

Interventions

Experimental group:Levosimendan

Control group:saline

Eligibility

Sex/Gender

All

Age

No minimum to 6 Years

Inclusion criteria

Inclusion criteria: 1. Congenital heart disease; 2. Aged less than 6 years; 3. NYHA cardiac functional class III to IV.

Exclusion criteria

Exclusion criteria: 1. Primary pulmonary disease especially pulmonary hypertension; 2. Insufficiency of liver and kidney function; 3. Severe arrhythmia, severe hypotension.

Design outcomes

Primary

Measure	Time frame
Levosimendan concentration;CTnI;cardiac uhrasonography;BNP;trachea cannula;	—

Countries

China

Contacts

Public ContactTan Qi

Shandong Provincial Hospital, Affiliated Hospital of Shandong University

81453381@qq.com+86 18753157303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 28, 2026